Bone Biologics Corp (BBLG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bone Biologics Corp (BBLG) has a cash flow conversion efficiency ratio of -0.132x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-518.44K) by net assets ($3.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Bone Biologics Corp stock valuation for the company's overall valuation and market capitalisation.
Bone Biologics Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Bone Biologics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bone Biologics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bone Biologics Corp ranked by their cash flow conversion efficiency. Explore Bone Biologics Corp cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pharos Energy plc
LSE:PHAR
|
0.058x |
|
Foncière Euris SA
PA:EURS
|
-0.116x |
|
Macfarlane Group PLC
LSE:MACF
|
0.103x |
|
Eco Oro Minerals Corp
F:GQQ
|
0.056x |
|
Airesis SA
SW:AIRE
|
0.045x |
|
New Energy Metals Corp
V:ENRG
|
0.045x |
|
Aclarion Inc
NASDAQ:ACON
|
-0.093x |
|
SRx Health Solutions Inc.
NYSE MKT:SRXH
|
18.676x |
Annual Cash Flow Conversion Efficiency for Bone Biologics Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of Bone Biologics Corp from 2012 to 2025. View BBLG share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.38 Million | $-2.69 Million | -0.500x | +57.74% |
| 2024-12-31 | $3.48 Million | $-4.12 Million | -1.184x | +63.99% |
| 2023-12-31 | $2.91 Million | $-9.56 Million | -3.288x | -448.21% |
| 2022-12-31 | $5.95 Million | $-3.57 Million | -0.600x | -220.99% |
| 2021-12-31 | $6.58 Million | $-1.23 Million | -0.187x | -699.23% |
| 2020-12-31 | $-13.69 Million | $-426.93K | 0.031x | -88.62% |
| 2019-12-31 | $-11.87 Million | $-3.25 Million | 0.274x | -42.62% |
| 2018-12-31 | $-8.60 Million | $-4.10 Million | 0.477x | +20.37% |
| 2017-12-31 | $-8.40 Million | $-3.33 Million | 0.397x | -53.27% |
| 2016-12-31 | $-8.63 Million | $-7.33 Million | 0.849x | +35.98% |
| 2015-12-31 | $-5.68 Million | $-3.55 Million | 0.624x | -16.23% |
| 2014-12-31 | $-3.70 Million | $-2.76 Million | 0.745x | +68218.73% |
| 2013-12-31 | $-5.61 Million | $-6.12K | 0.001x | -98.86% |
| 2012-12-31 | $-4.68K | $-447.00 | 0.096x | -- |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, a… Read more